Insider · CIK 0001202785
Eric Dobmeier
director
Files at JBIO (Jade Biosciences, Inc.), JANX (Janux Therapeutics, Inc.), GPCR (Structure Therapeutics Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 23, 2025 | GPCR Structure Therapeutics Inc. | AGrant or award Share Option (right to buy)derivative | +51,804 | $0.00 | $0 | 51,804 | Jun 25, 2025 |
| Jun 11, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +3,750 | $0.00 | $0 | 9,981 | Jun 13, 2025 |
| Jun 11, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,667 | $0.00 | $0 | 11,667 | Jun 13, 2025 |
| Apr 29, 2025 | JBIO Jade Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.